More than a month after the Indian drug regulator’s controversial approval of Biocon’s drug Itolizumab, new documents and the company’s own admissions raise serious doubts about the quality of the clinical trial Biocon conducted.
Based on this trial, which enrolled only 30 patients, the Central Drug Standards and Control Organisation (CDSCO) had on July 12 approved the use of Itolizumab in COVID-19 patients.
Now, worrying discrepancies have emerged between the claims made by Biocon’s chief medical officer Sandeep Athalye at a press conference on July 13 and how the trial was actually conducted. For example, even though Athalye said the trial had randomised 30 patients, five of these patients had actually not been randomised. And trial investigators didn’t record this fact on the Clinical Trials Registry of India (CTRI) website either.
Second, Athalye had said that the trial followed a commonly used design for emergency-use drug trials, called the Simon two-stage, which allows investigators to determine efficacy based on small sample sizes. But other experts pointed out that this design applies only to single-arm trials, while the Biocon Itolizumab trial had two arms.
Here's a video you can watch to understand what statistical significance is –https://www.youtube.com/watch?v=pwBW1aWic_Y or read this article by epidemiologist Jammi Nagaraj Rao: https://www.newslaundry.com/2020/08/28/how-can-we-be-sure-that-a-drug-treatment-for-covid-really-works
Read Priyanka Pulla's full story here – https://science.thewire.in/the-sciences/biocon-itolizumab-phase-ii-clinical-trial-cdsco-simon-two-stage-inconsistencies/
Like our work? Click here to support The Wire: https://thewire.in/support
The founding premise of The Wire is this: if good journalism is to survive and thrive, it can only do so by being both editorially and financially independent. This means relying principally on contributions from readers and concerned citizens who have no interest other than to sustain a space for quality journalism. As a publication, The Wire will be firmly committed to the public interest and democratic values.
We publish in four different languages!
For English, visit www.thewire.in
for Hindi: http://thewirehindi.com/
for Urdu: http://thewireurdu.com
for Marathi: https://marathi.thewire.in
If you are a young writer or a creator, you can submit articles, essays, photos, poetry – anything that’s straight out of your imagination – to LiveWire, The Wire’s portal for the young, by the young. https://livewire.thewire.in/
You can also follow The Wire’s social media platforms and engage with us.
Facebook
https://www.facebook.com/TheWire/
https://www.facebook.com/TheWireHindi/
https://www.facebook.com/TheWireUrdu/
https://www.facebook.com/TheWireMarathi/
Twitter
https://twitter.com/thewire_in
https://twitter.com/thewirehindi
https://twitter.com/TheWireUrdu
https://twitter.com/TheWireMarathi
https://twitter.com/livewire
Instagram
https://www.instagram.com/thewirein/
https://www.instagram.com/livewirein/
Don’t forget to hit the subscribe button to never miss a video from The Wire!
